HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
- Written by PR Newswire
![]() |
- HanAll will invest in Interon Laboratories, a preclinical-stage biotechnology company focused on treating complex neurological disorders
- Interon is developing a new category of immunotherapy for people with neurological and immune disorders starting with autism spectrum disorder
SEOUL, South Korea, Feb. 10, 2023 /PRNewswire/ -- HanAll Biopharma Co.,...
Read more: HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities















